Colorectal News and Research

RSS

IsoRay announces combination therapy study for prostate cancer

IsoRay Inc., announced today a new dual therapy study using Cesium-131 brachytherapy (internal radiation therapy) and external beam radiation. Multiple sites have now received Institutional Review Board (IRB) approval for this study which will examine the efficacy of combining intensity modulated radiation (IMRT) with Cesium-131 brachytherapy to treat intermediate and high risk early stage prostate cancer.

20 Jun 2011

Cancer Statistics 2011 report finds progress has not benefitted all segments of the population equally

A steady reduction in overall cancer death rates translates to the avoidance of about 898,000 deaths from cancer between 1990 and 2007, according to the latest statistics from the American Cancer Society.

18 Jun 2011

Cambridge Biomedical, Neogenix partner to develop ELISA assays for pancreatic and colorectal cancer

Neogenix Oncology, Inc. is pleased to announce it has signed an agreement with Cambridge Biomedical, Inc, based in Boston, MA, for the development of its pancreatic and colorectal cancer diagnostic serum ELISA assays.

16 Jun 2011

Ethicon Endo-Surgery introduces ENSEAL G2 Super Jaw advanced bipolar technology

To address surgeons' need for achieving strong vessel seals while remaining gentle on tissue in open surgery, Ethicon Endo-Surgery, Inc. (EES) today announces the launch of its innovative ENSEAL® G2 Super Jaw advanced bipolar technology.

15 Jun 2011

Colonoscopies done with suboptimal bowel preparation linked to high adenoma miss rates

A new study reports that colonoscopies done with suboptimal bowel preparation are associated with relatively high adenoma (precancerous polyp) miss rates, suggesting that suboptimal bowel preparation substantially decreases colonoscopy effectiveness and may mandate an early follow-up examination.

14 Jun 2011

GORE SEAMGUARD Bioabsorbable Staple Line Reinforcement receives Heath Canada approval

W. L. Gore & Associates, Inc. today announced at the American Society for Metabolic and Bariatric Surgery Meeting that it has received approval from Health Canada for GORE® SEAMGUARD® Bioabsorbable Staple Line Reinforcement. The device is specifically engineered to reduce the incidence of perioperative leaks and bleeding in a variety of open and minimally invasive surgeries.

13 Jun 2011

Tips for healthy barbecue

Some people may be reconsidering plans to grill hot dogs and steak based on a new report supporting the link between red and processed meats, and increased colorectal cancer risk. But, experts at The University of Texas MD Anderson Cancer Center say that small changes to what — and how — you grill can keep cancer off the menu.

10 Jun 2011

Mothers' B vitamin intake protects children against intestinal tumors

Mice born to mothers who are fed a diet supplemented with B vitamins are less likely to develop intestinal tumors, report scientists at the Jean Mayer USDA Human Nutrition Research Center on Aging (USDA HNRCA) at Tufts University.

10 Jun 2011

NKI, Agendia and MD Anderson collaborate for colorectal cancer research

Agendia, a commercial-stage molecular cancer diagnostics company, announces today that it has entered into a research collaboration with The University of Texas MD Anderson Cancer Center, one of the world's leading cancer centers and whose research program is considered one of the most productive in the world aimed solely at cancer, and the Netherlands Cancer Institute (NKI) with the aim of improving diagnosis and treatment options of colorectal cancer patients.

10 Jun 2011

National survey finds women more likely to see doctor on regular basis than men

A national survey found that women were three times more likely to see a doctor on a regular basis than men. Even though men on average die younger than women and have higher mortality rates for heart disease, cancer, stroke and AIDS, trying to get a man to a doctor can be harder than pulling teeth. So, why do men hate it so?.

9 Jun 2011

Eliminating ABCB5-expressing cells crucial for successful colorectal cancer treatment

Researchers at Children's Hospital Boston have found a marker called ABCB5 that both tags a small proportion of cells within colorectal cancers and fuels resistance in those cells to standard treatments. The results indicate that eliminating ABCB5-expressing cells is crucial for successful colorectal cancer treatment, while adding to the growing body of evidence for a theory of cancer growth called the cancer stem cell hypothesis.

9 Jun 2011

Increased blood clotting tendency linked to elevated bowel cancer risk

Back in the mid 19th century, a French doctor, Armand Trousseau, discovered a connection between cancer and thrombosis - the formation of often dangerous blood clots that can lead to venous occlusion.

7 Jun 2011

Ovarian cancer screenings do not reduce risk of death

A University of Alabama at Birmingham study released today reports that ovarian cancer screenings do not reduce a woman's risk of death from the disease and the invasive medical procedures may create associated health problems.

7 Jun 2011

Increases in VEGF-family markers in metastatic colorectal cancer patients associated with Avastin resistance

Circadian Technologies Limited announced today the presentation of data at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago USA associating resistance to Avastin with increases in plasma VEGF-C and D concentrations.

7 Jun 2011

Survivors of childhood cancer at increased risk of developing subsequent primary neoplasms

In a study that included nearly 18,000 children who had cancer, with follow-up of about 25 years, the greatest excess risk associated with a subsequent primary neoplasm (a new tumor) at older than age 40 years was for digestive and genitourinary neoplasms (related to the genital or urinary tract organs), according to a study in the June 8 issue of JAMA, a theme issue on cancer.

7 Jun 2011

Symphogen's Sym004 Phase 1 trial data on advanced solid tumors presented at ASCO 2011

Symphogen announced today preliminary primary endpoint data on 12 of 20 patients enrolled in the first Phase 1 clinical trial with their lead cancer compound, Sym004.

7 Jun 2011

DiagnoCure reports net loss of $1,601,439 for second quarter 2011

DiagnoCure, Inc., a life sciences company commercializing high‐value cancer diagnostic tests and delivering laboratory services, today reported financial and operation results for the second quarter of fiscal 2011.

7 Jun 2011

Cancer risk assessment in Lynch syndrome

Among various genetic mutations for individuals with Lynch syndrome, a hereditary cancer syndrome that carries a high risk of colon cancer and an above-normal risk of other cancers, researchers have identified mutations associated with a lower cancer risk and mutations associated with an increased risk for ovarian and endometrial cancer, according to a study in the June 8 issue of JAMA, a theme issue on cancer.

6 Jun 2011

Women with ovarian cancer do not benefit from CA-125 and transvaginal ultrasound

In a clinical trial that included nearly 80,000 women, those who received ovarian cancer screening did not have a reduced risk of death from ovarian cancer compared to women who received usual care, but did have an increase in invasive medical procedures and associated harms as a result of being screened, according to a study in the June 8 issue of JAMA, a theme issue on cancer.

6 Jun 2011

Recommendations on new cancer drug review process fall short in several ways: CCAC

While the Colorectal Cancer Association of Canada congratulates Quebec Health Minister Yves Bolduc on the recommendations of the report of the Working Group on the evaluation process of new anti cancer medications (Rapport du Groupe de travail sur le processus d'évaluation des médicaments anticancéreux) recently issued, the CCAC notes that the recommendations fall short in several important ways.

4 Jun 2011

Colorectal News and Research

IsoRay announces combination therapy study for prostate cancer

Cancer Statistics 2011 report finds progress has not benefitted all segments of the population equally

Cambridge Biomedical, Neogenix partner to develop ELISA assays for pancreatic and colorectal cancer

Ethicon Endo-Surgery introduces ENSEAL G2 Super Jaw advanced bipolar technology

Colonoscopies done with suboptimal bowel preparation linked to high adenoma miss rates

GORE SEAMGUARD Bioabsorbable Staple Line Reinforcement receives Heath Canada approval

Tips for healthy barbecue

Mothers' B vitamin intake protects children against intestinal tumors

NKI, Agendia and MD Anderson collaborate for colorectal cancer research

National survey finds women more likely to see doctor on regular basis than men

Eliminating ABCB5-expressing cells crucial for successful colorectal cancer treatment

Increased blood clotting tendency linked to elevated bowel cancer risk

Ovarian cancer screenings do not reduce risk of death

Increases in VEGF-family markers in metastatic colorectal cancer patients associated with Avastin resistance

Survivors of childhood cancer at increased risk of developing subsequent primary neoplasms

Symphogen's Sym004 Phase 1 trial data on advanced solid tumors presented at ASCO 2011

DiagnoCure reports net loss of $1,601,439 for second quarter 2011

Cancer risk assessment in Lynch syndrome

Women with ovarian cancer do not benefit from CA-125 and transvaginal ultrasound

Recommendations on new cancer drug review process fall short in several ways: CCAC

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News